Hello CCDPH Healthcare Partners,

**Postponement of review of the Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Year of Age**

On Friday, February 11, the FDA announced that it will postpone the VRBPAC meeting to discuss the request for authorization of Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years of age. The meeting had previously scheduled for Tuesday, February 15, 2022.

Also on Friday, February 11, Pfizer and BioNTech announced an extension of their rolling submission for the COVID-19 vaccine for children ages six months through four years of age.

- The postponement of the submission allows the FDA to evaluate additional data as Pfizer proceeds with its clinical trials of a third dose.
- The vaccine is a smaller dose than the vaccine for children ages 5-11.
- The trial of the vaccine for children six months through four years old included data from the first two doses of a three-dose series.
- The company expects to have data on the third dose by April.
- The company said in a statement Friday, “Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group.

CCDPH will provide updates and additional information when they become available.

-Cook County Department of Public Health